ClinicalTrials.gg
RecruitingNCT05365581Updated Sep 11, 2026

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

A Phase 1 interventional study of ASP2138 and Pembrolizumab in Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma and Pancreatic Adenocarcinoma, sponsored by Astellas Pharma Global Development, Inc.. Recruiting at 46 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
398
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Adenocarcinoma by Astellas Pharma Inc — 7 open to participants now, 9 under way, 4 of them phase 3. Adenocarcinoma · Astellas Pharma Inc.

Started
2022
the only one that year
Phase 1
3 of 12
1 open now
Registered
5th of 12
by date

Among the 12 studies in Adenocarcinoma by Astellas Pharma Inc, this one is the only one that started in 2022, is one of 3 in phase 1, and was the 5th registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

7 of the 12 studies in Adenocarcinoma by Astellas Pharma Inc are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Adenocarcinoma by Astellas Pharma Inc, or all of them as a file.
02

Study summary

Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein on a type of immune cell called a T-cell. This "tells" the immune system to attack the tumor. ASP2138 is a potential treatment for people with stomach cancer, gastroesophageal junction cancer (GEJ cancer) or pancreatic cancer. GEJ is where the tube that carries food (esophagus) joins the stomach. Before ASP2138 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. In this study, ASP2138 will either be given by itself, or given together with standard treatments for gastric, GEJ and pancreatic cancer. Pembrolizumab and mFOLFOX6, and ramucirumab and paclitaxel are standard treatments for gastric and GEJ cancer. mFOLFIRINOX is a standard treatment for pancreatic cancer. This information will help find a suitable dose of ASP2138 given by itself and together with the standard cancer treatments and to check for potential medical problems from the treatments.

The main aims of the study are:

  • To check the safety of ASP2138 and how well people can tolerate medical problems during the study.
  • To find a suitable dose of ASP2138 to be used later in the study.
  • These are done for ASP2138 given by itself and when given together with the standard cancer treatments.

Adults 18 years or older with stomach cancer, GEJ cancer, or pancreatic cancer can take part. Their cancer is locally advanced unresectable or metastatic. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. There should also be the CLDN18.2 marker in a tumor sample. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers, have specific infections, have a condition such as hemophagocytic lymphohistiocytosis (HLH) which is when the body over-reacts to a "trigger" such as infection, or have a specific heart condition ("New York Heart Association Class III or IV").

Phase 1: Lower to higher doses of ASP2138

  • ASP2138 is either given through a vein (intravenous infusion) or just under the skin (subcutaneous injection).
  • Different small groups are given lower to higher doses of ASAP2138.
  • ASP2138 is either given by itself, or given with 1 of 3 standard treatments:
  • Pembrolizumab and mFOLFOX6 (first treatment for gastric GEJ cancer)
  • Ramacirumab and paclitaxel (Second treatment for gastric or GEJ cancer)
  • ASP2138 with mFOLFIRINOX (first treatment for pancreatic cancer)

Phase 1b: doses of ASP2138 worked out from Phase 1

  • ASP2138 is either given through a vein or just under the skin. This depends on the findings from Phase 1.
  • People with gastric cancer, GEJ cancer or pancreatic cancer are given doses of ASP2138, worked out from Phase 1.
  • This includes doses of ASP2138 given by itself and ASP2138 given with the standard cancer treatments.
  • The standard cancer treatments given depends on the type of cancer they have.

End of treatment visit: This is 7 days after final dose of study treatment or if the study doctor decides to stop the person's treatment.

People who have locally advanced unresectable pancreatic cancer will not receive ASP2138 by itself.

03

Conditions studied

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Pancreatic Adenocarcinoma

Browse trials for

Keywords

  • Claudin (CLDN) 18.2
  • ASP2138
  • Pharmacokinetics
  • Safety
  • Tolerability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is considered an adult according to local regulation at the time of signing the form (ICF).
  • Female participant is not pregnant, confirmed by serum pregnancy test \&vmedical evaluation by interview \& at least 1 of the following conditions apply:

    • Not a woman of (WOCBP)
    • WOCBP who agrees to follow the guidance from the time of informed consent through at least 6 months after final study intervention administration.
  • Female participant must agree not to breastfeed starting at screening \& throughout the study period \& for 6 months after the final study intervention administration.
  • Female participant must not donate ova starting at screening \& throughout the study period \& for 6 months after the final study intervention administration.
  • Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period \& for 6 months after the final study intervention administration.
  • Male participant must not donate sperm during the treatment period \& for 6 months after the final study intervention administration.
  • Male participant with pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period \& for 6 months after the final study intervention administration.
  • Participant's tumor sample is positive for claudin (CLDN)18.2 expression by central immunohistochemistry (IHC) testing.
  • Participant has radiographically-confirmed, locally advanced, unresectable or disease within 28 days prior to the first dose of study intervention.
  • Participant has at least 1 according to (RECIST) 1.1 within 28 days prior to the first dose of study intervention. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Participant has by Fredericia (QTcF) =\< 470 msec.
  • Participant agrees not to participate in another interventional study while receiving study Intervention in the present study.
  • Participant has (ECOG) performance status of 0 or 1.
  • Participant has predicted >= 12 weeks.
  • Participant must meet all of criteria based on laboratory tests within 7 days prior to the first dose of study Intervention. In case of multiple laboratory data within this period, the most recent data should be used. If a participant has received a recent blood transfusion, the laboratory tests must be obtained >= 1 week after any blood transfusion.

Monotherapy Disease specific Criteria (MDSC): Gastric/GEJ Cancer

  • Participant has confirmed metastatic, locally advanced unresectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
  • Escalation: Participant with gastric/GEJ adenocarcinoma who has progressed, is intolerant, has refused, or for whom there is no standard approved therapies that impart significant clinical benefit (no limit to the number of prior treatment regimens).

    • Unique to South Korea: Participant with gastric/GEJ adenocarcinoma who has refused standard approved therapies is not allowed.
  • Expansion: Participant with gastric/GEJ adenocarcinoma must have received no more than 3 treatment.

    • Unique to EU: Expansion: Participant with gastric/GEJ adenocarcinoma must have received at least first-line standard therapies in the metastatic setting, must have received ramucirumab treatment if eligible \& where ramucirumab is available, \& no more than 3 prior lines of systemic chemotherapy treatment.

MDSC: Pancreatic Cancer

  • Participant has histologically or cytologically confirmed metastatic pancreatic adenocarcinoma.
  • Escalation: Participant with pancreatic adenocarcinoma who has progressed, is intolerant, has refused, or for whom there is no standard approved therapies that impart significant clinical benefit (no limit to the number of prior treatment regimens).

    • Unique to South Korea: Participant with pancreatic adenocarcinoma who has refused standard approved therapies is not allowed.
  • Expansion: Participants with pancreatic adenocarcinoma must have received no more than 2 prior lines of systemic chemotherapy treatment.

Note: Participants with locally advanced unresectable pancreatic adenocarcinoma will not be admitted in monotherapy arms.

  • Unique to EU: Participant with pancreatic adenocarcinoma must have received at least first-line standard therapies in the metastatic setting \& no more than 2 prior lines of systemic chemotherapy treatment.

For all participants in combination therapy (CT) administration:

  • If a participant has received a recent blood transfusion, the laboratory tests must be obtained ≥ 1 week after any blood transfusion.

Combination Therapy Disease-specific (CTDS) IC: ASP2138 in Combination with Pembrolizumab \& mFOLFOX6 as First-line Therapy in Gastric/GEJ Cancer

  • Participant has histologically confirmed diagnosis of gastric/GEJ adenocarcinoma.
  • Participant has metastatic or locally advanced unresectable gastric/GEJ adenocarcinoma.
  • Participant with gastric/GEJ adenocarcinoma has progressed \& must not have been previously treated for metastatic disease with either chemotherapy or prior therapy.
  • Participant has a human epidermal growth factor receptor 2 ()-negative tumor per local testing.
  • For CT with oxaliplatin, follow contraception guidelines from time of informed consent through at least 9 months after final study intervention.

(Unique to South Korea: For CT with oxaliplatin, follow contraception guidelines from time of informed consent through at least 15 months after final study intervention for women \& 12 months after final study intervention for men).

Unique to EU:

  • Participant must have a PD-L1 CPS ≥ 1.

CTDS IC: ASP2138 in Combination with Ramucirumab \& Paclitaxel as Second-line Therapy in Gastric/GEJ Cancer

  • Participant has histologically confirmed diagnosis of gastric/GEJ adenocarcinoma.
  • Participant has metastatic or locally advanced unresectable gastric/GEJ adenocarcinoma.
  • Participant with gastric/GEJ adenocarcinoma must have previously received 1 line of systemic chemotherapy treatment (i.e., documented objective radiological or clinical disease progression after first line platinum \& fluoropyrimidine treatment in the metastatic setting or disease progression during or within 4 months of the last dose of perioperative treatment.
  • For combination therapy with paclitaxel, female participant must follow contraception guidelines from time of informed consent through at least 7 months after final study intervention.

CTDS IC: ASP2138 in Combination with mFOLFIRINOX as First-line Therapy in Pancreatic Cancer

  • Participant has histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma.
  • Participant has confirmed metastatic or locally advanced unresectable pancreatic adenocarcinoma.
  • Participant has pancreatic adenocarcinoma, has progressed \& must not have received prior systemic anticancer therapy for their advanced disease. However, participants may have received either or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies as long as they were completed at least 6 months prior to enrollment and without disease progression or recurrence.
  • For CT with oxaliplatin, follow contraception guidelines from time of informed consent through at least 9 months after final study intervention.

(Unique to South Korea: For CT with oxaliplatin, follow contraception guidelines from time of informed consent through at least 15 months after final study intervention for women \& 12 months after final study intervention for men).

Japan \& Korea Specific:

For All Participants in ASP2138 in Combination with Pembrolizumab \& CAPOX:

- If a participant has received a recent blood transfusion, the laboratory tests must be obtained ≥ 1 week after any blood transfusion.

CTDS IC: ASP2138 in Combination with Pembrolizumab \& CAPOX as First-line Therapy in Gastric/GEJ Cancer

  • Participant has histologically confirmed diagnosis of gastric/GEJ adenocarcinoma.
  • Participant has metastatic or locally advanced unresectable gastric/GEJ adenocarcinoma.
  • Participant with gastric/GEJ adenocarcinoma must not have been previously treated for metastatic disease with either chemotherapy or prior checkpoint inhibitor therapy.
  • Participants have a HER2-negative tumor per local testing.
  • For CT with oxaliplatin, follow contraception guidelines from time of informed consent through at least 9 months after final study intervention.

Exclusion criteria

Exclusion Criteria (EC):

  • Participant has received other agents, or antineoplastic therapy including other immunotherapy or devices concurrently or within 21 days or 5 times the half-life, whichever is shorter, prior to first dose of study intervention administration.
  • Participant has any condition which makes the participant unsuitable for study participation.
  • Participant has known immediate or delayed or to any component of study intervention.
  • Participant has had prior severe allergic reaction or intolerance to known ingredients of ASP2138 or other antibodies, including humanized or chimeric antibodies.
  • Participant weighs \< 40 kg.
  • Participant has received systemic therapy, including systemic 14 days prior to first dose of study intervention. Participant using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 10 mg per day of prednisone or equivalent), receiving a single daily dose of systemic corticosteroids or receiving systemic corticosteroids as pre-medication for radiologic imaging contrast use are allowed.
  • Participant has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting.
  • Participant has significant gastric bleeding \&/or untreated gastric ulcers that exclude the participant from participation.
  • Participant has symptomatic or participant has evidence of unstable CNS metastases even if asymptomatic (e.g., progression on scans). Participants with previously treated CNS metastases are eligible, if they are clinically stable \& have no evidence of CNS progression by imaging for at least 4 weeks prior to start of study intervention \& are not requiring immunosuppressive doses of systemic steroids (> 10 mg per day of prednisone or equivalent) for longer than 2 weeks.
  • Participant is known to have infection. However, participants with cluster of differentiation (CD4) + T cell counts >= 350 cells/µL \& no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the past 6 months are eligible.
  • Participant is known to have active (positive hepatitis B surface antigen [HBsAg]) or infection. Testing is required for known history of these infections or as mandated by local requirements.

    • For participant who is negative for HBsAg, but hepatitis B core antibody (HBc Ab) positive, a hepatitis B virus deoxyribonucleic acid test will be performed \& if positive the participant will be excluded.
    • Participant with positive hepatitis C virus (HCV) serology, but negative HCV ribonucleic acid (RNA) test results are eligible.
    • Participant treated for HCV with undetectable viral load results are eligible
  • Participant has had within 6 months prior to first dose of study intervention any of the following: unstable angina, myocardial infarction, ventricular arrhythmia requiring intervention or hospitalization for heart failure.
  • Participant has active infection requiring systemic therapy that has not completely resolved within 7 days prior to the start of study intervention.
  • Participant has active disease that has required systemic immunosuppressive treatment within the past 1 month prior to the start of study intervention.
  • Participant has a disease or co-morbidity that may adversely affect the safe delivery of treatment within this study or make the participant unsuitable for study participation.
  • Participant has psychiatric illness or social situations that would preclude study compliance.
  • Participant has had a major surgical procedure 28 days before start of study intervention \& has not fully recovered.
  • Participant has received radiotherapy or for locally advanced unresectable gastric/GEJ or metastatic pancreatic adenocarcinoma 14 days prior to start of study intervention \& has NOT recovered from any related toxicity.
  • Participant has another for which treatment is required.
  • Participant who has received CLDN18.2-targeted therapy (e.g., zolbetuximab or chimeric antigen receptor CLDN18.2-specific T cells) prior to first dose of study intervention administration is not eligible for dose escalation cohorts. However, a participant who has received CLDN18.2-targeted therapy greater than 28 days or 5 half-lives (whichever is longer) prior to first dose study intervention administration is eligible for dose expansion cohorts only, with the exception of participants who have experienced Grade >= 3 gastrointestinal toxicity after receiving an CLDN18.2-targeted therapy.
  • Participant has a history or complication of interstitial lung disease.

China Specific:

Participant who has received treatment with herbal medications that have known antitumor activity within 28 days prior to first dose of study treatment.

For all participants in CT administration:

  • Participant has prior severe allergic reaction; suspected, known immediate or delayed hypersensitivity; or intolerance or contraindication to any study intervention (i.e., pembrolizumab \& mFOLFOX6 [all components], ramucirumab \& paclitaxel or mFOLFIRINOX [all components]).
  • For 5 FU (fluorouracil): Participant has known dihydropyrimidine dehydrogenase (DPD) deficiency.
  • Participants who have received systemic immunosuppressive therapy, including systemic corticosteroids 14 days prior to the first dose of study intervention are generally excluded; however, participants using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 10 mg per day of prednisone or equivalent), receiving a single daily dose of systemic corticosteroids or receiving systemic corticosteroids as pre-medication for radiologic imaging contrast or for chemotherapy (as part of CT administration) are allowed.
  • Participant is known to have HIV infection.
  • NOTE: Differing from monotherapy administration, participants with ≥ 350 cells/µL \& no history of AIDS-defining opportunistic infections within the past 6 months remain ineligible.
  • Participant has had uncontrolled high blood pressure within 6 months prior to the first dose of study intervention (Unique to EU: high blood pressure Stage 2 is defined as ≥ 140/90 mmHg).
  • Participant has a history of ascites requiring drainage more than twice in the past 7 days.

CTDS EC: ASP2138 in Combination with Pembrolizumab \& mFOLFOX6 as Therapy in Gastric/GEJ Cancer:

  • Participant has history of (non-infectious) pneumonitis that required steroids, current pneumonitis, or has a history of interstitial lung disease.
  • Participant received live-virus vaccination within 30 days prior to the first dose of study intervention.
  • Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention or has been diagnosed with an autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Patients that require replacement therapy (e.g., thyroxine [T4], insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) may be enrolled.

CTDS EC: ASP2138 in Combination with Ramucirumab \& Paclitaxel as Second-line Therapy in Gastric/GEJ Cancer:

  • History of cerebrovascular accident or within 6 months prior to study intervention.
  • Participant has significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study intervention.
  • Participant has evidence of a bleeding diathesis or significant coagulopathy.
  • Participant has initiated new treatment with medications that affect the coagulation cascade with an ≥ 2 such as vitamin K antagonists, heparins \& direct thrombin inhibitors or the use of factor Xa inhibitors within 28 days prior to the start of study intervention.

Note: If the participant started receiving such medications more than 28 days prior to the start of study intervention \& needs to continue, this is allowed. However, new anticoagulation medications may not be initiated within 28 days prior to the start of study intervention.

Japan \& Korea Specific:

For All Participants in ASP2138 in Combination with Pembrolizumab \& CAPOX:

  • Participant has prior severe allergic reaction; suspected, known immediate or delayed hypersensitivity; or intolerance or contraindication to any study intervention (i.e., pembrolizumab \& CAPOX [all components]).
  • Participants who have received systemic immunosuppressive therapy, including systemic corticosteroids 14 days prior to the first dose of study intervention are generally excluded, however, participants using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 10 mg per day of prednisone or equivalent), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as pre-medication for radiologic imaging contrast or for chemotherapy (as part of CT administration) are allowed.
  • Participant is known to have HIV infection.
  • NOTE: Differing from monotherapy administration, participants with CD4+ T cell counts ≥ 350 cells/μL \& no history of AIDS-defining opportunistic infections within the past 6 months remain ineligible.
  • Participant has had uncontrolled high blood pressure within 6 months prior to the first dose of study intervention.
  • Participant has a history of ascites requiring drainage more than twice in the past 7 days.
  • Participant has known DPD deficiency.

CTDS EC:

ASP2138 in Combination with Pembrolizumab \& CAPOX as First-line Therapy in Gastric/GEJ Cancer:

  • Participant has history of (noninfectious) pneumonitis that required steroids, current pneumonitis, or has a history of interstitial lung disease.
  • Participant received live-virus vaccination within 30 days prior to the first dose of study intervention.
  • Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention or has been diagnosed with an autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Participants who require replacement therapy (e.g., thyroxine [T4], insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) may be enrolled.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
398 participants (estimated)

Study arms

  • Experimental
    Monotherapy Dose Escalation (Phase 1)

    A dose escalation design will be used to determine the Maximum Tolerated Dose (MTD) and/ or the Recommended Phase 2 Dose (RP2D) regimens to be further evaluated in the Monotherapy Dose Expansion arms. Monotherapy Dose escalation part consists of six parts (Part A, B, C, D, E, and F), and approximately 86 patients would be enrolled in total. Participants will be assigned to sequentially escalating dose cohorts of ASP2138 in each part. The study will open with the Part A dosing schedule, while subsequent cohorts will be opened sequentially or in parallel based upon sponsor review of emerging data.

    Drug: ASP2138

  • Experimental
    Monotherapy Dose Expansion (Phase 1b) Gastric/GEJ cancer

    Participants will receive ASP2138 at the candidate RP2D regimens determined in Monotherapy Dose Escalation arm.

    Drug: ASP2138

  • Experimental
    Monotherapy Dose Expansion (Phase 1b) Pancreatic cancer

    Participants will receive ASP2138 at the candidate RP2D regimens determined in Monotherapy Dose Escalation arm.

    Drug: ASP2138

  • Experimental
    Combination Therapy Dose Escalation (Phase 1) Part G - First-line Gastric/GEJ Cancer

    A dose escalation design will be used to determine the MTD and/ or the RP2D regimens to be further evaluated in the Combination Dose Expansion arms. In combination dose escalation part G approximately 24 patients would be enrolled in total. Participants will be assigned to sequentially escalating dose cohorts of ASP2138 in combination with pembrolizumab and mFOLFOX6 as first line therapy.

    Drug: ASP2138 · Drug: Pembrolizumab · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil

  • Experimental
    Combination Therapy Dose Escalation (Phase 1) Part H - Second-line Gastric/GEJ Cancer

    A dose escalation design will be used to determine the MTD and/ or the RP2D regimens to be further evaluated in the Combination Dose Expansion arms. Participants will be assigned to sequentially escalating dose cohorts of ASP2138 in combination with ramucirumab and paclitaxel as second line therapy.

    Drug: ASP2138 · Drug: Ramucirumab · Drug: Paclitaxel

  • Experimental
    Combination Therapy Dose Escalation (Phase 1) Part I - First line Pancreatic Cancer

    A dose escalation design will be used to determine the MTD and/ or the RP2D regimens to be further evaluated in the Combination Dose Expansion arms. Participants will be assigned to sequentially escalating dose cohorts of ASP2138 in combination with mFOLFIRINOX as first line therapy.

    Drug: ASP2138 · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil · Drug: Irinotecan

  • Experimental
    ASP2138 + Pembrolizumab & mFOLFOX6 Combination Therapy Dose Expansion (Phase 1b) Gastric/GEJ Cancer

    Participants will receive candidate RP2D regimens of ASP2138 in combination with pembrolizumab \& mFOLFOX6 as first line therapy determined in Combination Therapy Dose Escalation arm.

    Drug: ASP2138 · Drug: Pembrolizumab · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil

  • Experimental
    ASP2138 + Ramucirumab & Paclitaxel Combination Therapy Dose Expansion (Phase 1b) Gastric/GEJ Cancer

    Participants will receive candidate RP2D regimens of ASP2138 in combination with ramucirumab and paclitaxel as second line therapy determined in Combination Therapy Dose Escalation arm.

    Drug: ASP2138 · Drug: Ramucirumab · Drug: Paclitaxel

  • Experimental
    ASP2138 + mFOLFIRINOX Combination Therapy Dose Expansion (Phase 1b) Pancreatic Cancer

    Participants will receive candidate RP2D regimens of ASP2138 in combination with mFOLFIRINOX as first line therapy in pancreatic cancer determined in Combination Therapy Dose Escalation arm in combination with mFOLFIRINOX as first line therapy in pancreatic cancer.

    Drug: ASP2138 · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil · Drug: Irinotecan

  • Experimental
    ASP2138 + Pembrolizumab & CAPOX CTDE Exploratory Cohort (Phase1b) Gastric/GEJ Cancer - Japan & Korea

    Participants will receive candidate RP2D regimens of ASP2138 in combination with pembrolizumab \& CAPOX as first line therapy determined in Combination Therapy Dose Escalation arm. CTDE: Combination Therapy Dose Expansion

    Drug: ASP2138 · Drug: Pembrolizumab · Drug: Oxaliplatin · Drug: Capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Dose Escalation)

    A DLT is defined as any of the prespecified Adverse Events (AEs) (graded using National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] version 5.0, except cytokine release syndrome \[CRS\] and immune effector cell-associated neurotoxicity syndrome \[ICANS\] which are graded using American Society for Transplantation and Cellular Therapy \[ASTCT\] consensus grading) or laboratory findings that the investigator or sponsor cannot clearly attribute to a cause other than study drug occurring during the DLT evaluation period.

    Time frame: Up to 28 days

  2. Number of participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator and events related to the (study) procedures.

    Time frame: Up to 27 months

  3. Number of participants with serious AEs (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other medically important events.

    Time frame: Up to 27 months

  4. Number of participants with laboratory value abnormalities

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to 25 months

  5. Number of participants with vital sign abnormalities

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to 27 months

  6. Number of participants with electrocardiogram (ECG) abnormalities

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to 24 months

  7. Number of participants with physical exam abnormalities

    Number of participants with potentially clinically significant physical exam values.

    Time frame: Up to 25 months

  8. Number of participants at each grade of the Eastern Cooperative Oncology Group (ECOG) performance status

    The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

    Time frame: Up to 25 months

Secondary outcomes

  1. Pharmacokinetics (PK) of ASP2138 in serum: Area under the concentration-time curve (AUC) from the time of dosing to the start of the next dosing interval at multiple dose conditions (AUCtau)

    AUCtau will be recorded from the PK serum samples collected.

    Time frame: Up to 12 months

  2. PK of ASP2138 in serum: maximum concentration (Cmax)

    Cmax will be recorded from the PK serum samples collected.

    Time frame: Up to 12 months

  3. PK of ASP2138 in serum: concentration immediately prior to dosing at multiple dosing (Ctrough)

    Ctrough will be recorded from the PK serum samples collected.

    Time frame: Up to 12 motnhs

  4. PK of ASP2138 in serum: time of the maximum concentration (Tmax)

    Tmax will be recorded from the PK serum samples collected.

    Time frame: Up to 12 months

  5. Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Phase 1b dose expansion)

    ORR is defined as the proportion of participants for each dosing scheme whose best overall response is rated as confirmed complete response (CR) or partial response (PR) per RECIST 1.1.

    Time frame: Up to 21 months

  6. Disease control rate (DCR) per RECIST 1.1 (Phase 1b dose expansion)

    DCR is defined as the proportion of participants for each dosing scheme whose best overall response is rated as confirmed CR, PR or stable disease (SD) per RECIST 1.1.

    Time frame: Up to 21 months

  7. Change from baseline in serum carbohydrate antigen 19-9 (CA19-9) (pancreatic only) (Phase 1b dose expansion)

    Serum CA19-9 level will be assessed by local laboratory in participants with pancreatic cancer.

    Time frame: up to 21 months

  8. Change from baseline in claudin (CLDN) 18.2 tumor expression level

    Comparison of CLDN18.2 expression in baseline versus on-treatment tumor biopsies will be performed.

    Time frame: Up to 6 weeks

  9. Change from baseline in programmed death-ligand 1 (PD-L1) tumor expression level

    Comparison of PD-L1 expression in baseline versus on-treatment tumor biopsies will be performed.

    Time frame: Up to 6 weeks

07

Study locations

42 of 46 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for May 2028, 71 months after the start.

Of 50 phase 1 interventional studies under Adenocarcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 64. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2022
First posted
May 9, 2022
StartActual
Jun 7, 2022
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05365581
Responsible party
Sponsor
First posted
May 9, 2022
Start date
Jun 7, 2022
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Sep 11, 2026

Study contacts

Astellas Pharma Global Development, Inc.
Contact
Astellas.registration@astellas.com
800-888-7704
Senior Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emaretamig

Start the discussion